Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on Antiretroviral Therapy after the Era of Test and Treat Strategy in Amhara Region, Ethiopia

Survival Dynamics: Mortality Rates and its... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/14-1267" }, "headline": "Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on...", "datePublished": "2025-11-17T15:43:48", "dateModified": "2025-11-17T15:43:48", "author": [ { "@type": "Person", "name": "Alemu Birara Zemariam" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Background Mortality rates after starting antiretroviral therapy (ART) remain higher in resource-limited areas compared to developed countries. In low-income settings, children often begin ART with higher viral loads and lower CD4 counts. Ethiopia’s national ART guidelines, introduced in 2014 based on WHO recommendations, advocate for universal ART for children to reduce mortality and improve health outcomes. However, there is limited data on mortality rates and their predictors since these guidelines were implemented. Therefore, this study was aimed to figure out these issues. Methods A retrospective cohort study was conducted on 612 children undergoing ART in Comprehensive Specialized Hospitals in the Amhara region of Ethiopia from January 1, 2015, to December 30, 2024. Participants were selected through simple random sampling. Data were processed using EPi Info 7 and analyzed in STATA-17, employing actuarial life table analysis to estimate mortality rates and Kaplan-Meier analysis for comparing time to death across groups. Cox proportional-hazard regression was applied to identify mortality predictors, using a significance level of P < 0.05. Results Of 602 included children initiated on ART during the follow-up period, 45(7.5%) died. The overall median (IQR) follow-up time was 47 (26-60) months. The overall death rate was 2.1 (95% CI: 1.6-2.8) per 100 person-years of follow-up. The predictors of mortality among children initiated ART were; Baseline CD4 count below the threshold [AHR: 2.6; 95% CI: 1.2-5.8], opportunistic infections [AHR: 3.7; 95% CI: 1.7-7.9], Poor adherence to treatment [AHR: 2.9; 95% CI: 1.4-5.7] and child caregiver with no formal education [AHR: 3.4; 95% CI: 1.1-11.6]. Conclusion The observed mortality rate exceeded the expected rate of under 5%. Key factors for higher mortality include low baseline CD4 counts, opportunistic infections, poor treatment adherence, and uneducated caregivers. Enhancing caregiver education, early detection of infections, and prompt ART initiation can help reduce mortality in these children. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/14-1267", "name": "Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected..." } } ] } Home Browse Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Zemariam AB. Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on Antiretroviral Therapy after the Era of Test and Treat Strategy in Amhara Region, Ethiopia [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1267 ( https://doi.org/10.12688/f1000research.171911.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on Antiretroviral Therapy after the Era of Test and Treat Strategy in Amhara Region, Ethiopia [version 1; peer review: 1 approved with reservations] Alemu Birara Zemariam https://orcid.org/0000-0001-8195-3011 Alemu Birara Zemariam https://orcid.org/0000-0001-8195-3011 PUBLISHED 17 Nov 2025 Author details Author details Department of Pediatrics and Child Health Nursing, School of Nursing, College of Medicine and Health Science, Woldia University, Woldia, Ethiopia, Woldia University, Weldia, Amhara, Ethiopia Alemu Birara Zemariam Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS This article is included in the Global Public Health gateway. Abstract Background Mortality rates after starting antiretroviral therapy (ART) remain higher in resource-limited areas compared to developed countries. In low-income settings, children often begin ART with higher viral loads and lower CD4 counts. Ethiopia’s national ART guidelines, introduced in 2014 based on WHO recommendations, advocate for universal ART for children to reduce mortality and improve health outcomes. However, there is limited data on mortality rates and their predictors since these guidelines were implemented. Therefore, this study was aimed to figure out these issues. Methods A retrospective cohort study was conducted on 612 children undergoing ART in Comprehensive Specialized Hospitals in the Amhara region of Ethiopia from January 1, 2015, to December 30, 2024. Participants were selected through simple random sampling. Data were processed using EPi Info 7 and analyzed in STATA-17, employing actuarial life table analysis to estimate mortality rates and Kaplan-Meier analysis for comparing time to death across groups. Cox proportional-hazard regression was applied to identify mortality predictors, using a significance level of P < 0.05. Results Of 602 included children initiated on ART during the follow-up period, 45(7.5%) died. The overall median (IQR) follow-up time was 47 (26-60) months. The overall death rate was 2.1 (95% CI: 1.6-2.8) per 100 person-years of follow-up. The predictors of mortality among children initiated ART were; Baseline CD4 count below the threshold [AHR: 2.6; 95% CI: 1.2-5.8], opportunistic infections [AHR: 3.7; 95% CI: 1.7-7.9], Poor adherence to treatment [AHR: 2.9; 95% CI: 1.4-5.7] and child caregiver with no formal education [AHR: 3.4; 95% CI: 1.1-11.6]. Conclusion The observed mortality rate exceeded the expected rate of under 5%. Key factors for higher mortality include low baseline CD4 counts, opportunistic infections, poor treatment adherence, and uneducated caregivers. Enhancing caregiver education, early detection of infections, and prompt ART initiation can help reduce mortality in these children. READ ALL READ LESS Keywords HIV/AIDS, ART, mortality, survival, predictors, children, Ethiopia Corresponding Author(s) Alemu Birara Zemariam ( [email protected] ) Close Corresponding author: Alemu Birara Zemariam Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2025 Zemariam AB. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Zemariam AB. Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on Antiretroviral Therapy after the Era of Test and Treat Strategy in Amhara Region, Ethiopia [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1267 ( https://doi.org/10.12688/f1000research.171911.1 ) First published: 17 Nov 2025, 14 :1267 ( https://doi.org/10.12688/f1000research.171911.1 ) Latest published: 17 Nov 2025, 14 :1267 ( https://doi.org/10.12688/f1000research.171911.1 ) Introduction The HIV epidemic poses a significant global challenge, with children bearing a disproportionate burden, particularly in developing countries. 1 Mother-to-child transmission (MTCT) remains the primary route of HIV infection in children, accounting for over 90% of paediatric cases, occurring during pregnancy, childbirth, or breastfeeding. 2 In the absence of effective interventions, the risk of transmission to infants born to HIV-positive mothers ranges from 20% to 45%. 3 , 4 However, with the implementation of prevention methods and antiretroviral therapy (ART), this risk can be reduced to below 5%. 1 , 5 In Ethiopia, as of 2020, approximately 44,138 children under the age of 15 are living with HIV, with an alarming 11,967 deaths annually attributed to HIV/AIDS-related causes. 6 , 7 Despite the provision of free ART services since 2005 and the establishment of over 1,474 health facilities offering care, 7 mortality rates among HIV-positive children remain high, particularly in resource-limited settings. 8 Children in these contexts often begin ART with higher viral loads and lower CD4 counts, leading to mortality rates ranging from 12.4 to 21.7 deaths per 1,000 child years. 9 , 10 Several factors influence mortality among these children, including WHO stage, CD4 count, anaemia, age, baseline functional status, and adherence to ART. 4 , 11 However, the evidence regarding the impact of the WHO stage, CD4 count, and cotrimoxazole preventive therapy (CPT) on mortality is inconsistent. 12 – 14 Early diagnosis and ART initiation have been demonstrated to significantly reduce child mortality and HIV progression, yet persist. 15 To address these issues, the national ART guidelines were updated in 2014 to recommend ART for all HIV-positive children under 15, 16 regardless of CD4 count or WHO stage. This study aimed to evaluate mortality rates and predictors among Ethiopian children following ART initiation, providing updated insights into the effectiveness of these interventions. Methods and materials Study design, period, and setting A multicentre retrospective follow-up study was conducted from January 1, 2015, to December 31, 2024. The study was conducted in Amhara region’s comprehensive specialized hospitals. These include Woldia, Dessie, Debrebirhan, Tibebe Gion, Debretabor, the University of Gondar, Felege Hiwot, and Debre Markos comprehensive specialized hospital. The hospitals serve more than 2.7 million, 2.5 million, 2.8 million, 4.5 million, 3.1 million, 7 million, 5 million, and 3.5 million peoples who came from the catchment area in their respective orders. Apart from other services, pediatric antiretroviral therapy services have been delivered in all public hospitals since 2005. From January 1, 2015, to December 31, 2024, a total of 1004 HIV-infected children aged younger than 14 years have been initiated ART services across these hospitals and all children were followed till the event of interest developed or become censored. Moreover, the follow-up was stopped when the child become adult (age >=15) during the course of treatment by considering them as right censored. From the eight hospitals, four comprehensive specialized hospitals were selected: University of Gondar hospital, Felege Hiwot, Woldia, and Debre Birhan hospital. Source population All children under 15 years of age started ART in Amhara region comprehensive specialized hospital. Study population All children under 15 years of age who started anti-retroviral therapy in four randomly selected Comprehensive hospitals in Amhara region after the implementation of the new guideline, from January 01, 2015, to December 31, 2024. Inclusion criteria Children aged less than 15 who started ART from January 01, 2015, to December 31, 2024, after the implementation of the new guideline. Exclusion Criteria include Incomplete patient charts on the day of ART initiation and children transferred out to other facilities during the study period were excluded from the study. Sample size determination and sampling technique Sample size determination The sample size was calculated using a double population proportion formula by Epi-Info 7. To determine the sample size, a cohort study conducted at Felege Hiwot Referral Hospital in Bahirdar, Ethiopia was considered. 17 In that study, the statistically significant predictors of mortality were taking cotrimoxazole prophylaxis, low hemoglobin level, delayed developmental milestone, and absolute CD4 count below the threshold. Therefore, the sample size was calculated using the mortality rate of 10% in children with low hemoglobin levels (exposed) and the mortality rate of 4% in children with normal hemoglobin levels (unexposed), by using 95% CI, with a 1:1 ratio, 80% power and 5% type I error. The resulting sample size was 204 in unexposed and 204 in exposed with a total sample size of 408. After multiplying by a design effect of 1.5 to adjust for the sampling error due to the two-stage sampling method we used and to increase the precision of the study estimates, the final sample size became 612. Sampling technique Among eight hospitals that had pediatric ART clinics in the region with strong pediatric HIV/AIDS care and treatment centers, four comprehensive hospitals (University of Gondar Hospital, Felege Hiwot, Woldia, and Debrebirhan) were randomly selected. The sample size was proportionally allocated to the four selected hospitals based on the number of target children. The records of children aged less than 15 who started anti-retroviral therapy from January 01, 2015, to December 31, 2024, were filtered from the database. Then, the required samples were selected from each of the four selected hospitals using simple random sampling. Study variables Independent variable The independent variables were socio-demographic and socio-economic characteristics and family care (child age, child sex, caregiver educational status, caregiver marital status, caregiver and caregiver employment status). Clinical and immunologic information like the presence of Tuberculosis (TB), TB treatment, opportunistic infections (OI), developmental milestones, WHO clinical stages, prophylaxis, anthropometric measurement, CD4 count, ART adherence, hemoglobin level, and ART treatment regimen. Dependent variable The dependent variable was the time to death of HIV-infected children after initiation of HAART. Data collection procedure A data extraction tool was used for recording the data from electronic databases and patient cards. This form was developed using a standardized ART entry and follow-up form employed by the ART clinic. The laboratory results recorded before starting ART were used as baseline values. If there was no pretreatment laboratory test, the results obtained within one month of ART initiation were considered baseline values. In each facility, two ART nurses collected the data, and the data collection was supervised by a trained supervisor. Data quality assurance The data review tool was carefully designed and prepared in the English language using a standardized ART entry and follow-up form employed by the ART clinic. Before actual data collection, a pre-test was done to check data review tool validity and reliability using 5% of the sample size in one of the facilities not selected for the actual study. The training was given to both data collectors and a supervisor about how to use data review tools, how to select study participants according to eligibility criteria, and how to collect the data. The filled record review tools were gathered and checked for completeness by the supervisor daily. The principal investigator also checked the data collection process and supervised overall research project activities. Data processing and analysis After data entry was completed, the data was exported and analyzed using Stata software. Data cleaning followed by exploration was undertaken to see if there were items that were not logical and then subsequent edits were made. The patients’ cohort characteristics were described in terms of mean with standard deviation (SD) and median value with interquartile range (IQR) for continuous data and in terms of frequency and percentage for categorical data. The study participants were followed from the date of ART initiation until the occurrence of death confirmed by reviewing medical registration in the hospital or registration by ART adherence supporters (from patient card) or, date lost to follow up (last visit) or the end date of the follow-up period (December 31, 2024). During analysis, the status of each participant was dichotomized into censored or death. Life Table analysis was carried out to estimate the mortality rate of children and Kaplan Meier survival curve with a log-rank test was fitted to test for the presence of a difference in survival time among different predictor variables. Cox-proportional hazard regression analysis was used to identify predictors of time to death. Multicollinearity between predictor variables was checked using variance inflation factors (VIF) and there was no multicollinearity between predictor variables. The proportionality of the hazard assumption was checked using the Log (-Log) S (t) plots. The crude and adjusted hazard ratios with their 95% confidence intervals (CI) were estimated and a p-value less than 0.05 was used to declare the presence of a significant association between time to death and covariates. Results Socio-demographic characteristics of the child and caregiver From the 612 reviews done, 10 patient cards were excluded with many missing values, and 602 cards were reviewed which gave an enrollment rate of 98.3%. The mean age of children under follow-up was 7 years with a standard deviation (SD) of 4 years. Regarding the sex of the children, 318 (52.8%) of them were males. The majority of the caregivers, 356 (64.6%), were married, 390 (72.5%) had primary level and above educational status and 222 (41.4%) were government-employed. Regarding the place of residence, 394 (78.2%) live in the catchment area of the hospitals ( Table 1 ). Table 1. Socio-demographic characteristics of children on ART in Comprehensive hospitals and their caregivers, Amhara region, Ethiopia, 2016-2020. Characteristics Censored number (%) Dead number (%) Total number (%) Age of the children Below 1 year 20 (3.6) 1 (2.2) 21 (3.5) 1-5 years old 199 (35.7) 26 (57.8) 225 (37.4) 6 to 10 years 160 (28.7) 10 (22.2) 170 (28.2) Above 10 years 178 (32.0) 8 (17.8) 186 (30.9) Sex of the children Male 290 (52.1) 28 (62.2) 318 (52.8) Female 267 (47.9) 17 (37.8) 284 (47.2) Caregiver marital status (n=551) Married 333 (65.8) 23 (51.1) 356 (64.6) Single 64 (12.6) 3 (6.7) 67 (12.2) Divorced 63 (12.5) 11 (24.4) 74 (13.4) Widowed 46 (9.1) 8 (17.8) 54 (9.8) Caregiver’s educational status (n=538) No formal education 128 (25.9) 20 (45.5) 148 (27.5) Primary education 187 (37.9) 18 (40.9) 205 (38.1) Secondary education 103 (20.9) 3 (6.8) 106 (19.7) Tertiary and above 76 (15.4) 3 (6.8) 79 (14.7) Caregiver occupation (n=536) Housewife 120 (24.4) 17 (38.6) 137 (25.6) Merchant 69 (14.0) 7 (15.9) 76 (14.2) Government employee 209 (42.5) 13 (29.5) 222 (41.4) Daily laborer 62 (12.6) 4 (9.1) 66 (12.3) Others 32 (6.5) 3 (6.8) 35 (6.5) Living in the catchment area (n=504) Yes 363 (78.1) 31 (79.5) 394 (78.2) No 102 (21.9) 8 (20.5) 110 (21.8) Baseline clinical, laboratory, and ART information Among under five years children, 172 (91.9%) had an appropriate developmental status at admission and among five years and older children about 379 (93.5%) of them had working functional status. Regarding the WHO clinical staging of the children at the baseline, 157 (26.1%) of them were at WHO clinical stage two, and 222 (36.9%) of children were at WHO clinical stage three. The CD4 count at the baseline was below the threshold among 227 (38.9%) of the children and 105 (19.2%) were found to be anemic during the baseline hemoglobin measurement ( Table 2 ). Table 2. Baseline clinical, laboratory, and ART information of children on ART in comprehensive hospitals, Amhara, Ethiopia, 2015-2024. Characteristics Censored number (%) Dead number (%) Total number (%) Developmental status (for children 5 years) (n=402) Working 358 (94.2) 18 (81.8) 376 (93.5) Ambulatory 17 (4.5) 3 (13.6) 20 (5.0) Bedridden 5 (1.3) 1 (4.6) 6 (1.5) WHO Clinical stage at enrolment Stage I 88 (15.8) 2 (4.4) 90 (15.0) Stage II 152 (27.3) 5 (11.1) 157 (26.1) Stage III 209 (37.5) 13 (28.9) 222 (36.9) Stage IV 108 (19.4) 25 (55.6) 133 (22.1) CD4 counts (n=583) Above WHO CD4 threshold 346 (64.3) 13 (28.9) 356 (61.1) Below the WHO CD4 threshold 192 (35.7) 32 (71.1) 227 (38.9) Anemia (n=547) Yes 94 (18.6) 11 (26.2) 105 (19.2) No 411 (81.4) 31 (73.8) 442 (80.8) Medical follow-up of children and ART information From the total of 602 children under follow-up, 269 (44.7%) developed OI, and diarrhea and TB were the common OIs; 94 (34.9%) and 75 (27.9%) respectively. CPT is given to children under ART either as a prophylaxis or as a treatment for different OIs and 436 (72.4%) of children took CPT. Similarly, anti-TB drugs were given to the children under ART either as a prophylaxis or as a treatment for those who had TB, and 92 (15.3%) of the total children under follow-up took these anti-TB drugs. Regarding the children in the follow-up ART drug regimen, the majority of them took first-line ART regimen particularly; 287 (47.7%) of the children took 4g and 4f ART drug regimen and 184 (30.6%) them took 4j and 1j ART drug regimen. Only 14 (2.3%) took the second-line ART regimen. Among the total of 602 children under follow-up, 468 (77.7%) had a good or fair ARV treatment adherence while the rest 62 (10.3%) had poor adherence to ARV treatment ( Table 3 ). Table 3. Children follow-up medical and ART information of children on ART in Amhara region Comprehensive Specialized hospitals, Amhara, Ethiopia, 2015-2024. Characteristics Censored number (%) Dead number (%) Total number (%) Opportunistic infections No OIs 324 (58.2) 10 (22.2) 334 (55.5) Diarrhea 86 (15.4) 8 (17.8) 94 (15.6) Pneumonia 36 (6.5) 12 (26.7) 48 (8.0) Tuberculosis 62 (11.1) 12 (26.7) 74 (12.3) Other OIs 49 (8.8) 3 (6.7) 52 (8.6) CPT Prophylaxis/Treatment No 158 (28.4) 8 (17.8) 166 (27.6) Yes 399 (71.6) 37 (82.2) 436 (72.4) TB Prophylaxis/Treatment No 478 (85.8) 32 (71.1) 510 (84.7) Yes 79 (14.2) 13 (28.9) 92 (15.3) ART regimen 4g and 4f 261 (46.9) 26 (57.8) 287 (47.7) 4j and 1j 173 (31.1) 11 (24.4) 184 (30.6) 4d and 4e 77 (13.8) 3 (6.7) 80 (13.3) Other first-line regimens 34 (6.1) 3 (6.7) 37 (6.1) 2nd line 12 (2.2) 2 (4.4) 14 (2.3) ARV treatment adherence Good and fair 507 (91.0) 31 (68.9) 538 (89.4) Poor 50 (9.0) 14 (31.1) 64 (10.6) Incidence of death during the follow-up Of the total children who were initiated on ART under the follow-up period, 45 (7.5%) of them died, 468 (77.7%) were alive and 89 (14.8%) were lost from follow-up. The overall median (IQR) follow-up time was 47 (26-60) months with a total follow-up time of 2140 years. The overall death rate was 2.1 (95% CI: 1.6-2.8) per 100 person-years of follow-up. The cumulative survival probabilities of HIV-infected children after 6, 12, 36, and 60 months of ART initiation were 98%, 97%, 93% and 89% respectively ( Table 4 ). Table 4. Life Table analysis of children on ART in Comprehensive hospitals, Amhara, Ethiopia, 2015-2024. Interval start time Number entering interval Number withdrawing in interval Number exposed to risk Number of terminal events Proportion of terminating Proportion of surviving Cumulative proportion of surviving 0 602 6 599 0 .00 1.00 1.00 6 596 31 580 10 .02 .98 .98 12 555 30 540 6 .01 .99 .97 18 519 28 505 8 .02 .98 .96 24 483 56 455 3 .01 .99 .95 30 424 29 409 4 .01 .99 .94 36 391 49 366 4 .01 .99 .93 42 338 38 319 2 .01 .99 .92 48 298 54 271 3 .01 .99 .91 54 241 70 206 4 .02 .98 .90 60 167 166 84 1 .01 .99 .89 Comparison of the survival function Using the Kaplan-Meir survival function, the survival experience of children was assessed among different categories of predictors. Among all independent variables, four children’s status and two caregiver characteristics showed significant differences within the different categories. Under five children have a shorter survival experience than children older than five years (Log-rank test X 2 -value=12.9, P-value=0.002). Children with OIs have shorter survival experiences than those without OIs (Log-rank test X 2 -value =24.4, P-value=0.0001). The survival experience of children who took TB prophylaxis/treatment during the follow-up was significantly longer than those who didn’t take TB prophylaxis/treatment (Log-rank test X 2 -value =8.3, P-value=0.004). Children with good and fair ARV adherence have longer survival experiences than those with poor ARV treatment adherence (Log-rank test X 2 -value=20.9, P-value=0.0001). Children with normal CD4 count at the baseline assessment have longer survival experiences than those with below the threshold CD4 count (Log-rank test X 2 -value=25.1, P-value=0.0001). Similarly, children with baseline WHO classification of stage I & II have longer survival experiences than those with baseline WHO classification of stage III & IV (Log-rank test X 2 -value =7.2, P-value=0.007) ( Figures 1 - 4 ). Figure 1. Kaplan-Meier estimate of survival with Opportunistic infections (OIs) among children on ART in Comprehensive hospitals, Amhara, Ethiopia, 2015–2024. Figure 2. Kaplan-Meier estimate of survival with WHO clinical stage among children on ART in Comprehensive hospitals, Amhara, Ethiopia, 2015–2024. Figure 3. Kaplan-Meier estimate of survival with ARV treatment adherence among children on ART in Comprehensive hospitals, Amhara, Ethiopia, 2015–2024. Figure 4. Kaplan-Meier estimate of survival with CD4 counts status among children on ART in Comprehensive hospitals, Amhara, Ethiopia, 2015–2024. From the caregiver characteristics; children with a caregiver of no educational status had shorter survival experiences than those who attended a formal educational status (Log-rank test X 2 -value=13.3, P-value=0.004). Finally, children from a married caregiver had a longer survival experience than children from a widowed or divorced caregiver (Log-rank test X 2 -value=11.1, P-value=0.01). Predictors of survival of children under ART drugs The Cox proportional regression model was used to determine the predictors of survival of HIV-infected children. Before fitting the covariate into the model, the proportional hazard assumption was checked by examining Log (-Log S (t)) plots. Overall, five variables; child age, CD4 counts, WHO Clinical Stage, OI, ART adherence, and Caregiver educational status were found to be significantly associated with time to death. According to the final Cox proportional regression model, children with a baseline CD4 count below the threshold were 2.6 times more likely to die than those children with normal baseline CD4 count [AHR: 2.6; 95% CI: 1.2-5.8], children with OIs during the follow up were 3.7 times more likely to die than children without OIs during the follow-up time [AHR: 3.7; 95% CI: 1.7-7.9]. Likewise, those who had poor ARV adherence are nearly three times more likely to die than their counterparts [AHR: 2.9; 95% CI: 1.4-5.7]. In addition, children whose caregivers with no formal educational status were 3.4 times more likely to die than those children with caregiver educational status of tertiary or above education [AHR: 3.4; 95% CI: 1.1-11.6] ( Table 5 ). Table 5. Cox Regression analysis of predictors of mortality among children on ART in Comprehensive hospitals, Amhara, Ethiopia, 2015-2024. Characteristics Censored number (%) Dead number (%) CHR (95% CI) AHR (95% CI) Child Age < 5 years 174 (88.3) 23 (11.7) 3.6 (1.6-8.0) * 1.8 (0.7-4.7) 5-10 years 205 (93.6) 14 (6.4) 1.6 (0.7-3.9) 1.6 (0.6-3.9) Above 10 years 178 (95.7) 8 (4.3) 1 1 CD4 counts Below threshold 192 (85.7) 32 (14.3) 4.5 (2.4-8.7) * 2.6 (1.2-5.8) ** Above threshold 346 (96.4) 346 (96.4) 1 1 WHO Clinical Stage Stage I/II 243 (95.7) 11 (4.3) 1 Stage III/IV 314 (90.2) 34 (9.8) 4.3 (1.9-9.6) * 1.2 (0.5-2.4) Opportunistic Infection Yes 233 (86.9) 233 (86.9) 4.9 (2.4-9.9) * 3.7 (1.7-7.9) ** No 324 (97.0) 10 (3.0) 1 1 ART adherence Good/Fair 507 (94.2) 31 (5.8) 1 1 Poor 50 (78.1) 14 (21.9) 3.2 (1.7-6.2) * 2.9 (1.4-5.7) ** Caregiver education No education 128 (86.5) 18 (8.8) 3.9 (1.2-13.3) * 3.4 (1.1-11.6) ** Primary education 187 (91.2) 18 (8.8) 2.3 (0.7-7.8) 2.6 (0.7-8.8) Secondary Education 103 (97.2) 3 (2.8) 0.7 (0.2-3.6) 0.7 (0.1-3.3) Tertiary and above 76 (96.2) 3 (3.8) 1 1 * = Significant under bivariable analyses, ** = Significant in multivariable analysis. Discussion This research determined the incidence of mortality rate and its predictors in younger than 14 years children who had been on ART in Amhara region Comprehensive Specialized Hospitals, Ethiopia. The study found that the overall incident rate of mortality among children who are on ART was 2.1 per 100 person-years of follow-up. The current finding was comparable with most studies done in Ethiopia. 18 – 23 However, this finding was relatively lower than the mortality incidence rate reported in other studies in Ethiopia; which ranged from 3.2 to 6.3 per 100 person-years. 10 , 21 – 26 Similarly, it is lower than most reports from sub-Saharan African countries, 27 – 30 ranging from 2.9 deaths per 100 child years in Zimbabwe 31 to 6.9 deaths per 100 child years in Mozambique, 32 and in India 3 deaths per 100 child-years. 33 These differences might be related to the variations in sample size, study setting, follow-up period, study participants’ clinical characteristics, quality of ART services, and awareness of patients’ caregivers to comply with the advice of the counselors. 30 , 34 Ethiopia launched the national ART guideline in 2014 based on the 2013 WHO guideline which recommends ART for all children less than 15 years regardless of CD4 counts and WHO clinical stages. The lower rate of death rate in this research reflected that this country’s ART program has been effective in improving the survival rate of children in Ethiopia and suggests early initiation of ART in children with close monitoring during follow-up could further reduce mortality. 34 The research indicated that the rate of death among children with a baseline CD4 count below the threshold was significantly higher than those children with a normal baseline CD4 count. This finding is also supported by other similar previous studies in Ethiopia. 35 – 39 After progressive depletion of CD4+ T cells, the risk of opportunistic infections increases. Antiretroviral therapy (ART) can suppress viral replication; improve the CD4+ T cell counts and re-establish the immunity to fight against infections. 34 , 40 However, studies also found poor immunological recovery and survival in patients who initiated ART at low CD4 counts. 41 Studies conducted in northern Ethiopia also revealed lower immunological recovery among immunosuppressed children with HIV after initiation of ART. 42 , 43 Moreover, HIV patients with poor immune recovery have been shown to have a higher risk of developing associated comorbidities and death. 34 This study also found that children who had poor ARV treatment adherence died nearly three times faster rate than their good ART adherence counterparts. Similarly, studies have shown that good adherence to ART medications among children infected with HIV was significantly associated with their longer survival. 21 , 22 , 25 This is because antiretroviral medication adherence is necessary to obtain the full benefit of ART drugs. 34 On the other hand, poor adherence to ART could attributed to a failure in suppression of viral replication, reduction of the viral load, and failure to enhance the patients’ immunity levels making the child susceptible to developing opportunistic infections and causing mortality. 42 , 43 It might also result in treatment failure by increasing the chance of mutation that can cause a drug-resistant virus leading to death. 34 , 40 , 41 This poor adherence could be related to insufficient counselling and education of caregivers and inadequate knowledge of caregivers. 44 , 45 Caregiver’s educational level was also a significant predictor of children’s mortality rate. Children whose caregivers had no formal educational status had a significantly higher risk of mortality than those children with caregiver tertiary or above educational status. Similarly, maternal educational status was significantly associated with mortality in a study done in Axum, Ethiopia. 25 This could be due to the more educated caregivers having better knowledge regarding the disease as well as its management including the understanding of the instructions provided by health care providers working in ART clinics that could help the child to have relatively better medication compliance adhering to ART treatments and enhanced the child’s health outcomes. 44 , 45 On the contrary, children with caregivers with no education could be attributed to the children’s poor adherence to ART which could negatively affect the suppression of viral replication, increasing the risk of drug resistance and treatment failure which increased the risk of death. 34 The result also revealed that the rate of death among children with OI during the follow-up time was significantly higher than children without OIs. This finding is supported by reports from Ethiopia and other developing countries which document that HIV-infected children presenting with OIs at ART initiation had a higher risk of mortality. 26 – 28 Research from Ethiopia 39 and Tanzanian 46 found that children who had comorbidities like TB at ART initiation had a lower rate of survival. Likewise, studies done in Ethiopia 36 and South Africa 47 reported opportunistic infection of chronic diarrhea as a determinant of mortality among HIV-infected children. Patients could also die as a result of the side effects and drug toxicity of the common drugs used to treat these infections besides the direct effect of these opportunistic infections. Research revealed that HIV-infected patients treated with anti-TB medications usually experience drug toxicity as compared to HIV-uninfected persons. 48 Since opportunistic comorbidities are the leading causes of poor health outcomes including mortality in HIV-infected patients in Ethiopia, the country’s national ART guidelines strongly recommend treating OIs before ART initiation. 49 The finding of this study suggested that the current mortality rate of children on ART in Amhara region comprehensive hospitals is above the expected 5% mortality rate among children on ART. Therefore, close monitoring should be given for children who had CD4 counts below the WHO threshold and those children with OIs. Drug adherence of the patients should be assessed with caution as it will determine the survival status of the children. Furthermore, the caregivers’ knowledge and other similar individual factors need to be in consideration, since they are the ones who follow their medications. Limitations I want to inform our readers that the incidence of death may be undermined by the absence of survival data on the patient card, hence we, considered them as lost follow-up. Also, incomplete information concerning important variables like nutritional status and other clinical variables was not found, which might confound the results. In addition, the exact day of lost follow-up is unknown which may reduce the survival time which could affect the estimations and the need to get adequate information about the cause of death to identify the actual cause of death for those patients reported as dead. Ethics approval and consent to participate Ethical clearance was obtained from University of Gondar, College of Medicine and Health Sciences, Ethical Clearance Review Committee on March 25, 2024 with protocol number 456/2024. The Institutional Review Board decision, and consent waiver was obtained from the Ethics committee because the data was secondary source (patients charts). Then, the data were collected after getting a permission letter from each hospital and Amhara public health institute. Information in the data abstraction tool was confidentiality kept. This study was done in compliance with the Declaration of Helsinki. Consent for publication None. Data availability The datasets generated and analysed during the current study are not publicly available due to the highly sensitive nature of the clinical data involving a vulnerable population (HIV-infected children) and the conditions of the ethical approval granted by the University of Gondar, College of Medicine and Health Science Ethics Committee. However, de-identified data will be made available to qualified researchers for the purpose of replicating the study findings, subject to a formal data access agreement. Requests should be directed to the corresponding author at [email protected] . Acknowledgements I would like to extend our gratitude to heads and health providers working in ART clinics of selected hospitals for their kind cooperation and support. I also thank different workforces that participated in the data collection of this study. References 1. WHO: Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. WHO; 2010. 2. Giuliano M, Andreotti M, Liotta G, et al. : Maternal antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Malawi: maternal and infant outcomes two years after delivery. PLoS One. 2013; 8 (7): e68950. PubMed Abstract | Publisher Full Text | Free Full Text 3. World Health, Organization: Guideline on the public health response to pretreatment HIV drug resistance.2020. 4. UNAIDS: Global AIDS monitoring 2017: indicators for monitoring the 2016 United Nations Political Declaration on HIV and AIDS. Geneva: 2017. 5. WHO: Guidelines on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. WHO; 2015. 6. Institute Ethiopian Public Health: National HIV Related Estimates and Projections.2020. 7. Health Federal Democratic Republic of Ethiopia Ministry of: National Strategic Plan for the Elimination of Mother-to-Child Transmission of HIV and Syphilis (EMTCT of HIV & Syphilis).2017. 8. Victoria S, Sarah R, Tsitsi B, et al. : CD4+ cell count recovery following initiation of HIV antiretroviral therapy in older childhood and adolescence. AIDS. 2018; 32 (14): 1977–1982. Publisher Full Text 9. Health Federal Ministry of: National Guidelines for Comprehensive HIV Prevention, Care, and Treatment.2017. 10. Mekonnen DLU, History D of E: Infant and Child Mortality in Ethiopia.2011. 11. Modi S, Chiu A, Ng’eno B, et al. : Understanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings. AIDS. 2013; 27 Suppl 2 (0 2): S159–S167. PubMed Abstract | Publisher Full Text 12. Ababa A: HIV Related Estimates and Projections for Ethiopia – March 2017.2017. 13. Health Ethiopian Federal Ministry of: Health Sector Transformation Plan.2015. 14. Gesesew HA, et al. : Early Mortality Among Children and Adults in Antiretroviral Therapy Programs in Southwest. PLoS One. 2018; 13 : 2003–2015. Publisher Full Text 15. World Health Organization: UNAIDS, Global scale-up of antiretroviral therapy. UNAIDS. State of the AIDS epidemic. 2017; 2021 . 16. Ethiopia Ministry of Health of: National Guidelines for HIV & AIDS Care and Treatment.2014. 17. Nations United: Declaration P. GLOBAL AIDS Monitoring.2017. 18. Granich R, Gupta S, Hersh B, et al. : Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990-2013. PLoS One. 2015; 10 (7): e0131353. PubMed Abstract | Publisher Full Text | Free Full Text 19. Wamalwa DC, Obimbo EM, Farquhar C, et al. : Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort. BMC Pediatr. 2010; 10 : 33. PubMed Abstract | Publisher Full Text | Free Full Text 20. Mwiru RS, et al. : Nutritional Status and Other Baseline Predictors of Mortality Among HIV-Infected Children Initiating Antiretroviral Therapy in Tanzania. J. Int. Assoc. Provid. AIDS Care. 2015; 14 (2): 172–179. PubMed Abstract | Publisher Full Text | Free Full Text 21. Aregay G, Solomon G, Fisaha H, et al. : Predictors of mortality among HIV infected children on anti-retroviral therapy in Mekelle Hospital, Northern Ethiopia: a retrospective cohort study. BMC Public Health. 2013; 13 : 1–6. 22. Bitew S, Mekonen A, Assegid M: Predictors of Mortality of HIV-Infected Children After Initiation of Antiretroviral Treatment in Wolaita Zone Health Facilities, Ethiopia: Retrospective Cohort Study. J. AIDS HIV Res. 2017; 9 (4): 89–97. 23. Negese KD, Awoke AT, Megabiaw ZB: Predictors of mortality among children on antiretroviral therapy at a referral hospital, Northwest Ethiopia: a retrospective follow up study. BMC Pediatr. 2012; 12 : 1–7. 24. Mulugeta A, Henok A, Tewelde T, et al. : Determinants of Survival Among HIV Positive Children on Antiretroviral Therapy in Public Hospitals, Addis Ababa. Ethiopia. AIDJ. 2017; 25 : 235–241. 25. Kidane T, Fisaha H, Neway H: Predictors of mortality among patients enrolled on antiretroviral therapy in Aksum hospital, northern Ethiopia: a retrospective cohort study. PloS one. 2014; 9 (1): e87392. Publisher Full Text 26. Mulualem BG, Haileselassie EE, Demsie AA: Late antiretroviral therapy initiation and associated factors among children on antiretroviral therapy at University of Gondar Comprehensive Specialized Hospital, Gondar, Northwest Ethiopia: a cross-sectional study. BMC. Res. Notes. 2019; 12 : 1–7. 27. Belay GM, Engeda EH, Ayele AD: Late antiretroviral therapy initiation and associated factors among children on antiretroviral therapy at University of Gondar Comprehensive Specialized Hospital, Gondar, Northwest Ethiopia: a cross-sectional study. BMC. Res. Notes. 2019; 12 : 255. PubMed Abstract | Publisher Full Text | Free Full Text 28. Biru M, et al. : Rates and predictors of attrition among children on antiretroviral therapy in Ethiopia: A prospective cohort study. PLOS ONE. 2018; 13 (2): e0189777. PubMed Abstract | Publisher Full Text | Free Full Text 29. Kedir A: Factors Affecting Survival of HIV Positive Children Taking Antiretroviral Therapy at Adama Referral Hospital and Medical College, Ethiopia. Journal of AIDS & Clinical Research. 2014; 5. 30. Ismael A, Seblewengel L: Mortality among pediatric patients on HIV treatment in sub-Saharan African countries: a systematic review and meta-analysis. BMC Public Health. 2019; 19 (1): 149. Publisher Full Text 31. McHugh G, et al. : Clinical outcomes in children and adolescents initiating antiretroviral therapy in decentralized healthcare settings in Zimbabwe. J. Int. AIDS Soc. 2017; 20 (1): 21843. PubMed Abstract | Publisher Full Text | Free Full Text 32. Maria L, Josue L, Batya E, et al. : Patients enrolled in HIV care in Mozambique: baseline characteristics and follow-up outcomes. JAIDS. J. Acquir. Immune Defic. Syndr. 2011; 58 (3): e75–e86. Publisher Full Text 33. Mohan JU, Neeraj D, Yujwal R, et al. : Survival of Children Living with Human Immunodeficiency Virus on Antiretroviral Therapy in Andhra Pradesh, India. Indian Pediatr. 2018; 55 (4): 301–305. Publisher Full Text 34. WHO. World Health Organization: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization; 2nd ed. 2016. 35. Abrha GH, Paul W, Kifle W, et al. : Prevalence, trend and risk factors for antiretroviral therapy discontinuation among HIV-infected adults in Ethiopia in 2003-2015. PLOS ONE. 2017; 12 (6): e0179533. Publisher Full Text 36. Aregay G, Solomon G, Fisaha H, et al. : Predictors of mortality among HIV infected children on anti-retroviral therapy in Mekelle Hospital, Northern Ethiopia: a retrospective cohort study. BMC Public Health. 2013; 13 (1): 1047. Publisher Full Text 37. Animut A, Haileselassie EE, Mekonnen KM, et al. : Mortality rate among HIV-positive children on ART in Northwest Ethiopia: a historical cohort study. BMC Public Health. 2020; 20 (1): 1303. Publisher Full Text 38. Arage G, Assefa M, Worku T: Survival rate of HIV-infected children after initiation of the antiretroviral therapy and its predictors in Ethiopia: A facility-based retrospective cohort.2019; 7 : 2050312119838957. 39. Sidamo NB, Hebo SH: Survival time and its predictors among HIV-infected children after antiretroviral therapy in public health facilities of Arba Minch town, Gamo Gofa Zone, Southern Ethiopia. Ethiop. J. Health Dev. 2018; 14 (2). Publisher Full Text 40. Vidya Vijayan KK, Priyadarshini KK, Tripathi Srikanth P, et al. : Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections. Front. Immunol. 2017; 8 : 580. PubMed Abstract | Publisher Full Text | Free Full Text 41. Kelley CF, Kitchen CM, Hunt PW, et al. : Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 2009; 48 (6): 787–794. PubMed Abstract | Publisher Full Text | Free Full Text 42. Desta AA, Kidane KM, Bahta YW, et al. : Determinants of immunological recovery following HAART among severely immunosuppressed patients at enrolment to care in Northern Ethiopia: a retrospective study.2020; 10 (8): e038741. 43. Fozia O, Mengist Y: Virological Failure and Associated Risk Factors among HIV/AIDS Pediatric Patients at the ART Clinic of Jimma university Medical Center, Southwest Ethiopia. The Open AIDS Journal. 2020; 14 : 61–67. Publisher Full Text 44. Aklilu E, Nega T, Setegn E, et al. : Adherence to Highly Active Antiretroviral Therapy Among Children in Ethiopia: A Systematic Review and Meta-analysis. AIDS Behav. 2018; 22 (8): 2513–2523. Publisher Full Text 45. Dachew BA, Tesfahunegn TB, Birhanu AM: Adherence to highly active antiretroviral therapy and associated factors among children at the University of Gondar Hospital and Gondar Poly Clinic, Northwest Ethiopia: a cross-sectional institutional based study. BMC Public Health. 2014; 14 : 875. PubMed Abstract | Publisher Full Text | Free Full Text 46. Zanoni BC, Thuli P, Zanoni Holly M, et al. : Risk Factors Associated with Increased Mortality among HIV Infected Children Initiating Antiretroviral Therapy (ART) in South Africa. PLOS ONE. 2011; 6 (7): e22706. PubMed Abstract | Publisher Full Text | Free Full Text 47. Mwiru RS, Spiegelman D, Duggan C, et al. : Nutritional Status and Other Baseline Predictors of Mortality among HIV-Infected Children Initiating Antiretroviral Therapy in Tanzania. J. Int. Assoc. Provid. AIDS Care. 2015; 14 (2): 172–179. PubMed Abstract | Publisher Full Text | Free Full Text 48. Mark D, Michael A, David C, et al. : Factors That Complicate the Treatment of Tuberculosis in HIV-Infected Patients. J. Acquir. Immune Defic. Syndr. 1999; 2005 (39): 464–470. 49. Federal Minstry of Health: National Guidelines for Comprehensive Hiv Prevention, Care and Treatment.2017. Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 17 Nov 2025 ADD YOUR COMMENT Comment Author details Author details Department of Pediatrics and Child Health Nursing, School of Nursing, College of Medicine and Health Science, Woldia University, Woldia, Ethiopia, Woldia University, Weldia, Amhara, Ethiopia Alemu Birara Zemariam Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Visualization, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (1) version 1 Published: 17 Nov 2025, 14:1267 https://doi.org/10.12688/f1000research.171911.1 Copyright © 2025 Zemariam AB. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Zemariam AB. Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on Antiretroviral Therapy after the Era of Test and Treat Strategy in Amhara Region, Ethiopia [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1267 ( https://doi.org/10.12688/f1000research.171911.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 17 Nov 2025 Views 0 Cite How to cite this report: Hutahaean BSH. Reviewer Report For: Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on Antiretroviral Therapy after the Era of Test and Treat Strategy in Amhara Region, Ethiopia [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1267 ( https://doi.org/10.5256/f1000research.189576.r434388 ) The direct URL for this report is: https://f1000research.com/articles/14-1267/v1#referee-response-434388 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 02 Jan 2026 Bona Sardo Hasoloan Hutahaean , Maastricht University, Maastricht, The Netherlands Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.189576.r434388 This article presents an important contribution to the literature by examining mortality rates and predictors among children living with HIV in Ethiopia. The findings indicate that low CD4 counts, opportunistic infections, poor adherence to antiretroviral therapy (ART), and caregivers’ lower ... Continue reading READ ALL This article presents an important contribution to the literature by examining mortality rates and predictors among children living with HIV in Ethiopia. The findings indicate that low CD4 counts, opportunistic infections, poor adherence to antiretroviral therapy (ART), and caregivers’ lower educational levels are significant predictors of mortality among children with HIV. Overall, the manuscript demonstrates a coherent structure, consistent use of terminology, appropriate citation of relevant studies, and a clear contribution to improving HIV care, particularly for pediatric populations. To further enhance the quality and clarity of the manuscript, I offer the following suggestions for revision: INTRODUCTION 1. Please provide more detailed explanations of the key factors influencing mortality among children with HIV. For example, clarify what is meant by WHO clinical staging, specify CD4 count thresholds associated with increased mortality risk, and explain key terms such as anemia, age, baseline functional status, and adherence to ART. 2. The statement “However, the evidence regarding the impact of the WHO stage, CD4 count, and cotrimoxazole preventive therapy (CPT) on mortality is inconsistent” requires further elaboration. Please clarify what these inconsistencies are across previous studies and explicitly state how the current study aims to address or contribute to resolving these discrepancies. 3. Please expand on the argument presented in the statement: “Early diagnosis and ART initiation have been demonstrated to significantly reduce child mortality and HIV progression, yet persist.” It would be helpful to clarify what challenges or gaps persist despite early diagnosis and ART initiation. 4. The final paragraph of the introduction would benefit from the inclusion of more relevant and recent literature to strengthen the rationale and underscore the importance of the current study. METHODS 1. The sections describing the source population, study population, and inclusion and exclusion criteria could be consolidated into a single, concise narrative describing the study participants. 2. Please provide a clearer justification for the selection of the four hospitals used for data collection, including their relevance or representativeness for the study population. DISCUSSION Consider incorporating more recent and relevant studies that highlight the importance of ART adherence and HIV-related knowledge in improving outcomes among people living with HIV, such as: https://doi.org/10.3390/tropicalmed8030138 https://doi.org/10.1080/09540121.2024.2414080 2. Provide a clear conclusion and further recommendations for future studies. REFERENCES 1. Please update the reference list by including more recent and relevant literature, preferably from the last ten years, to strengthen the manuscript’s theoretical and empirical grounding. Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? I cannot comment. A qualified statistician is required. Are all the source data underlying the results available to ensure full reproducibility? No source data required Are the conclusions drawn adequately supported by the results? Partly References 1. Hutahaean B, Stutterheim S, Jonas K: Barriers and Facilitators to HIV Treatment Adherence in Indonesia: Perspectives of People Living with HIV and HIV Service Providers. Tropical Medicine and Infectious Disease . 2023; 8 (3). Publisher Full Text 2. Hutahaean B, Stutterheim S, Jonas K: The role of fear as a barrier and facilitator to antiretroviral therapy initiation in Indonesia: insights from patients and providers. AIDS Care . 2025; 37 (1): 161-177 Publisher Full Text Competing Interests: No competing interests were disclosed. Reviewer Expertise: Determinants in HIV care. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Hutahaean BSH. Reviewer Report For: Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on Antiretroviral Therapy after the Era of Test and Treat Strategy in Amhara Region, Ethiopia [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1267 ( https://doi.org/10.5256/f1000research.189576.r434388 ) The direct URL for this report is: https://f1000research.com/articles/14-1267/v1#referee-response-434388 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 17 Nov 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 Version 1 17 Nov 25 read Bona Sardo Hasoloan Hutahaean , Maastricht University, Maastricht, The Netherlands Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2026 Hutahaean B. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 02 Jan 2026 | for Version 1 Bona Sardo Hasoloan Hutahaean , Maastricht University, Maastricht, The Netherlands 0 Views copyright © 2026 Hutahaean B. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This article presents an important contribution to the literature by examining mortality rates and predictors among children living with HIV in Ethiopia. The findings indicate that low CD4 counts, opportunistic infections, poor adherence to antiretroviral therapy (ART), and caregivers’ lower educational levels are significant predictors of mortality among children with HIV. Overall, the manuscript demonstrates a coherent structure, consistent use of terminology, appropriate citation of relevant studies, and a clear contribution to improving HIV care, particularly for pediatric populations. To further enhance the quality and clarity of the manuscript, I offer the following suggestions for revision: INTRODUCTION 1. Please provide more detailed explanations of the key factors influencing mortality among children with HIV. For example, clarify what is meant by WHO clinical staging, specify CD4 count thresholds associated with increased mortality risk, and explain key terms such as anemia, age, baseline functional status, and adherence to ART. 2. The statement “However, the evidence regarding the impact of the WHO stage, CD4 count, and cotrimoxazole preventive therapy (CPT) on mortality is inconsistent” requires further elaboration. Please clarify what these inconsistencies are across previous studies and explicitly state how the current study aims to address or contribute to resolving these discrepancies. 3. Please expand on the argument presented in the statement: “Early diagnosis and ART initiation have been demonstrated to significantly reduce child mortality and HIV progression, yet persist.” It would be helpful to clarify what challenges or gaps persist despite early diagnosis and ART initiation. 4. The final paragraph of the introduction would benefit from the inclusion of more relevant and recent literature to strengthen the rationale and underscore the importance of the current study. METHODS 1. The sections describing the source population, study population, and inclusion and exclusion criteria could be consolidated into a single, concise narrative describing the study participants. 2. Please provide a clearer justification for the selection of the four hospitals used for data collection, including their relevance or representativeness for the study population. DISCUSSION Consider incorporating more recent and relevant studies that highlight the importance of ART adherence and HIV-related knowledge in improving outcomes among people living with HIV, such as: https://doi.org/10.3390/tropicalmed8030138 https://doi.org/10.1080/09540121.2024.2414080 2. Provide a clear conclusion and further recommendations for future studies. REFERENCES 1. Please update the reference list by including more recent and relevant literature, preferably from the last ten years, to strengthen the manuscript’s theoretical and empirical grounding. Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? I cannot comment. A qualified statistician is required. Are all the source data underlying the results available to ensure full reproducibility? No source data required Are the conclusions drawn adequately supported by the results? Partly References 1. Hutahaean B, Stutterheim S, Jonas K: Barriers and Facilitators to HIV Treatment Adherence in Indonesia: Perspectives of People Living with HIV and HIV Service Providers. Tropical Medicine and Infectious Disease . 2023; 8 (3). Publisher Full Text 2. Hutahaean B, Stutterheim S, Jonas K: The role of fear as a barrier and facilitator to antiretroviral therapy initiation in Indonesia: insights from patients and providers. AIDS Care . 2025; 37 (1): 161-177 Publisher Full Text Competing Interests No competing interests were disclosed. Reviewer Expertise Determinants in HIV care. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Hutahaean BSH. Peer Review Report For: Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected Pediatric Patients on Antiretroviral Therapy after the Era of Test and Treat Strategy in Amhara Region, Ethiopia [version 1; peer review: 1 approved with reservations] . F1000Research 2025, 14 :1267 ( https://doi.org/10.5256/f1000research.189576.r434388) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/14-1267/v1#referee-response-434388 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Survival Dynamics: Mortality Rates and its...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/14-1267/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/14-1267/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/14-1267/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Zemariam AB'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/14-1267/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/14-1267", templates : { twitter : "Survival Dynamics: Mortality Rates and its Predictors among HIV-Infected.... Zemariam AB, published by " + "@F1000Research" + ", https://f1000research.com/articles/14-1267/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/171911/189576") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "189576"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "443268": 0, "443266": 0, "443267": 0, "443264": 0, "443265": 0, "436390": 0, "436391": 0, "436388": 0, "436389": 0, "436386": 0, "436387": 0, "436385": 0, "436394": 0, "436392": 0, "436393": 0, "445638": 0, "448966": 0, "445639": 0, "448967": 0, "448965": 0, "445646": 0, "448974": 0, "445647": 0, "445644": 0, "448972": 0, "445645": 0, "448973": 0, "445642": 0, "448970": 0, "445643": 0, "448971": 0, "445640": 0, "448968": 0, "445641": 0, "448969": 0, "434390": 0, "434391": 0, "434388": 5, "434389": 0, "434386": 0, "434387": 0, "434385": 0, "434394": 0, "434392": 0, "434393": 0, "443262": 0, "443263": 0, "443260": 0, "443261": 0, "443259": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "8cf59aac-74c6-4ef6-bbfa-06d2817ed9cc"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });